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Autoimmunity and chronic viral infections are recurrent clinical observations in Myalgic
Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), a complex disease with an
unknown cause. Given these observations, the regulatory CD4+ T cells (Tregs) show
promise to be good candidates for the underlying pathology due to their capacity to
suppress the immune responses against both self and microbial antigens. Here, we
discussed the overlooked role of these cells in the chronicity of Human Herpes Virus
6 (HHV6), Herpes Simplex 1 (HSV1), and Epstein–Barr virus (EBV), as often reported as
triggers of ME/CFS. Using simulations of the cross-regulation model for the dynamics of
Tregs, we illustrated that mild infections might lead to a chronically activated immune
responses under control of Tregs if the responding clone has a high autoimmune
potential. Such infections promote persistent inflammation and possibly fatigue. We then
hypothesized that ME/CFS is a condition characterized by a predominance of this type
of infections under control of Tregs. In contrast, healthy individuals are hypothesized to
trigger immune responses of a virus-specific clone with a low autoimmune potential.
According to this hypothesis, simple model simulations of the CD4+ T-cell repertoire
could reproduce the increased density and percentages of Tregs observed in patients
suffering from the disease, when compared to healthy controls. A deeper analysis of
Tregs in the pathogenesis of ME/CFS will help to assess the validity of this hypothesis.
Keywords: viral infection, autoimmunity, immunological theory, immunological tolerance and regulation,
hypothesis, mathematical modeling, disease pathology
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INTRODUCTION
ME/CFS is a debilitating illness of unknown cause characterized
by a persistent fatigue, post-exertion malaise, unrestful sleep,
frequent infections, and other non-specific symptoms (1, 2).
Most of the patients trigger the disease during adulthood after
a viral infection (3). Human herpes 6 virus (HHV6), Epstein–
Barr virus (EBV), and Herpes simplex virus 1 (HSV1) are just
a few examples of possible infection triggers reported for the
disease (4). As a possible consequence of these infections, patients
often show an activated immune system with the presence of
a high quantity of autoantibodies. Given these observations,
some authors hypothesized an autoimmune origin for the disease
(5, 6). If true, an impairment of key immune-cell populations
controlling autoimmunity, such as the regulatory T CD4+ cells
(Tregs), should be implicated in the pathogenesis of ME/CFS.
Tregs represent a small subset of the CD4+ T cells that are
able to suppress the effector activity of conventional CD4+ T
cells (Teffs) and other immune cells. These cells are molecularly
identified by the activation marker CD25 and the transcription
factor FOXP3 (7, 8). The constitutive expression of the foxp3
gene in CD4+ T cells after thymic T-cell development is the
hallmark of the natural Tregs (9). In turn, a subset of CD4+ T
cells can express the foxp3 gene in the periphery upon antigen
stimulation. These cells are called induced or adaptable Tregs
(9). Both types of Tregs are thought to recognize tissue antigens
mainly, which ensures the regulation of potentially damaging
responses against the body. This hypothesis comes from the
observation that the deletion of Tregs or the suppression of their
regulatory activity leads to severe and generalized autoimmune
responses in inbred mice and humans (10–12). In addition,
a reduction of these cells in the periphery is in the origin
of naturally occurring type I diabetes in the NOD mouse
strain (13).
Until now, the role of Tregs on the pathogenesis of ME/CFS
has been simply assessed by comparing the respective
cell counts between patients and healthy controls. With
the exception of a single study (14), the percentage of
Tregs tends to be increased in patients when compared
to healthy controls (15–17). Similar tendency was found
for the transforming growth factor beta (TGFβ), the
Treg-associated suppression cytokine (18, 19). These
clinical observations were considered a paradox under the
postulated autoimmune origin for ME/CFS (5). However,
they prompted us to consider an alternative hypothesis for
the pathogenesis of ME/CFS according to which Tregs are
elevated resulting from chronic infections that are cross-reactive
with self-antigens.
The present paper aims then to present different T-cell and
viral dynamics consistent with this hypothesis using the cross-
regulation model for the immune-physiology of Tregs (20–22).
With this purpose, we first introduce the basic immunological
Abbreviations: cAPC, cognate antigen-presenting cell; EBV, Epstein–Barr virus;
HHV6, Human Herpes virus 6; HSV1, Human simplex virus 1; ME/CFS, myalgic
encephalomyelitis/chronic fatigue syndrome; TGFβ, transforming growth factor
beta; Treg, regulatory T cell; Teff, effector T cell.
theory suggested by this model. We then extend this theory for
the role of Tregs in the presence of HHV6, EBV, and HSV1
infections, which helps to discuss their impact on Tregs and on
the pathogenesis of ME/CFS.
THE CROSS-REGULATION MODEL FOR
CD4+ T-CELL DYNAMICS AND ITS
EXTENSION FOR CHRONIC VIRAL
INFECTIONS
The cross-regulation model describes the dynamics of Tregs and
effector T cells (Teffs) and their mutual interaction dependent
on multicellular conjugates with cognate antigen-presenting cells
(cAPCs) (Figure 1) (20, 23). Conjugation and deconjugation
with cAPC are assumed to be the basic cellular process by which
Tregs and Teffs become activated and then proliferate; otherwise,
they would die by apoptosis with a given rate (Figure 1A).
The model assumes that Teffs can only proliferate following
productive conjugations with their cAPCs in absence of Treg co-
conjugation (Figure 1B). In contrast, Tregs can only proliferate
when co-conjugated with Teffs on the same cAPC (Figure 1C).
In that case, Treg proliferation occurs upon receiving growth
signals or factors provided by Teffs. At the same time, Tregs are
assumed to send a molecular signal (e.g., via TGFβ) that inhibits
the proliferation of Teffs (Figure 1D). It is worth noting that this
mechanism is mathematically equivalent to a related one where
some Teffs are induced to become Tregs (Figure 1E). If these
two mechanisms are in place, then the proliferation rate of Tregs
should be increased in relation to the one of Teffs. A detailed
discussion supporting these model assumptions can be found
elsewhere (20). Mathematically speaking, the model used in this
article was deeply simplified, but still captures the complex non-
linear effects of Treg immunophysiology and its conjugation with
cAPC. A detailed description of this simplified model is provided
in Supplementary File.
For simplicity, the CD4+ T-cell repertoire of a given
individual is divided intomultiple independent clones containing
both Tregs and Teffs. Each clone is associated with a specific
set of cAPC with a given abundance in the periphery and the
respective dynamics is described by the cross-regulation model.
Independence between clones in the repertoire simplifies the
analysis as one only needs to interpret all possible dynamics of
a single clone associated with a given set of cAPC. This implies
that Tregs and Teffs from the same clone cross-regulate each
other, but the same cells from different clones do not; a model
assuming a cross-regulation between distinct clones can be found
elsewhere (21).
In this discussion article, we also consider an extension of the
basic cross-regulation model to the scenario where individuals
are infected by HHV6, HSV1, and EBV at some point of their
lifetime. The detailed description of the respective mathematical
model is presented in Supplementary File. The main purpose
of this extended model is to provide a quantitative framework
where the role of Tregs on the pathogenesis of ME/CFS can
be discussed.
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FIGURE 1 | Conceptual scheme of the cross-regulation model under the assumption of cAPC with two conjugation sites. (A) Tregs and Teffs will eventually die by
cellular apoptosis if they are not conjugated and activated by their cAPC. (B) Teffs are able to proliferate when conjugated with their cAPCs occupied by other Teffs.
(C) Tregs are not able to proliferate when conjugated with a cAPC occupied by other Tregs. (D) When Tregs and Teffs occupy different conjugation sites in the same
cAPC, the former proliferates by receiving a signal (or a growth factor) from the latter. At the same time, Tregs send a signal that suppresses the proliferation of Teffs.
(E) When Tregs and Teffs occupy different conjugation sites in the same cAPC, both cell populations are able to proliferate, but the latter will convert to a Treg
phenotype after some time. This alternative mechanism is mathematically equivalent to the one shown in (D) but the proliferation rate of Tregs is expected to be higher
than the one of Teffs.
IMMUNOLOGICAL THEORY BASED ON
THE CROSS-REGULATION MODEL
A simple immunological theory can be constructed using a
steady-state analysis of the basic cross-regulation model (20).
This theory helps to understand how autoimmunity, microbial
immunity, and ME/CFS can be reconciled. In this theory, the
peripheral CD4+ T-cell repertoire is assumed to be composed
of independent clones that allow the determination of the
steady states of a generic T-cell clone in isolation as function
of the abundance of the respective cAPC in the periphery,
while considering the remaining model parameters fixed at
their reference value. For this analysis, we introduce the term
“autoimmune potential” of a particular clone as the abundance
of the associated cAPC in the periphery.
There are three qualitatively distinct steady states for the
dynamics of a clone depending on its autoimmune potential
(Figure 2A). On one extreme, there is a steady state where this
clone undergoes extinction because its autoimmune potential
is below a critical persistence (or survival) cutoff. This clone is
expected to react to either microbial antigens or very rare tissue
antigens before undergoing extinction (20). In the context of
viruses with a strong CD4+ T-cell tropism, clonal extinction
might be beneficial for the host as it exhausts the cellular source
used for viral replication. On the other extreme, there is a
steady state in which both Tregs and Teffs can be maintained
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FIGURE 2 | Basic immunological theory based on the cross-regulation model. (A) The steady-states for the density of Teffs and Tregs belonging to a given clone as a
function of the density of a given cAPC where dotted, dotted–dashed, and dashed vertical cutoffs refer to the limits on cAPC density for T-cell survival, bi-stability, and
regulation by Tregs. The shaded area represents the cAPC densities that can only maintain Teffs in equilibrium under initial conditions of 0.90 and 0.10 for Teffs and
Tregs, respectively. The bi-stability cutoff represents the minimum cAPC density upon which system reaches a bi-stable regime. That is, depending on the initial
conditions for Tregs and Teffs, the system would reach either a steady state with Teffs (solid red line) or a steady state with co-existence of Teffs and Tregs (dashed red
and green lines, respectively). For the generation of this plot, the cross-regulation model was simulated for 25,000 units of time and for each value of cAPC density
with the remaining parameters fixed at the respective reference values (Table S1). (B) Example of a possible distribution of clones generated by a thymic output of a
healthy individual, where the shaded area represents the cAPC densities associated with clones with an intermediate autoimmune potential. The limits of the shaded
area refer to the T-cell survival and regulation cutoff values shown in (A). For illustrative purposes, the distribution of clones follows a Gamma random variable whose
shape and rate parameters (θ1 = 3.84 and θ2 = 2.25, respectively) were determined by equating the hypothetical 1% and 96% quantiles with the survival and
regulation cutoff values shown in (A). (C) Possible natural variation of the regulation cutoff in a given population assuming that the shaded area represents the
regulation cutoff values associated with putative healthy individuals of the population. Again, for illustrative purposes, the distribution was illustrated with a Gamma
probability distribution whose shape and rate parameters (θ1 = 89.24 and θ2 = 25.13, respectively) were determined by equating the 1% and 96% quantiles to the
arbitrary values 0.15 and 0.25, respectively.
together in the same clone, because the autoimmunity potential
of the clone is above a critical regulation cutoff. This clone is
predicted to recognize and react to ubiquitous tissue antigens
whose immune responses against them are under control of
Tregs in absence of infection. However, if a microbial antigen
has by chance a high molecular mimicry with these self-antigens,
then the respective microbe might become chronic due to a
permanent suppression of the underlying immune response
promoted by Tregs. Such situation is expected to contribute to a
chronic inflammation and fatigue often associated with ME/CFS.
The last steady state emerges between these two extreme cases
and results from the dynamics of a clone where only Teffs
can be maintained at equilibrium. In theory, this clone has an
intermediate autoimmune potential and, thus, it should react
to less abundant self-antigens and/or infections. By hypothesis,
putative autoimmunity responses induced by the Teffs of this
clone are under check by a bystander suppression that the model
does not account for.
The peripheral CD4+ T-cell repertoire of a given individual
should be then partitioned into three types of clones according
to the above steady states. In theory, T-cell development in the
thymus should impose qualitative restrictions on the fraction of
clones associated with each of the steady states. On one hand,
clones that just respond to very rare antigens are likely to not
encounter their cognate antigens during T-cell development and,
therefore, they would be purged from the repertoire due to
lack of enough stimuli. On the other hand, developing clones
recognizing highly abundant antigens with high affinity should
be removed from the T-cell repertoire as they might trigger
deleterious autoimmune responses when reaching the periphery.
Then, a “healthy” thymic output should consist of a few clones
that responding to rare or highly abundant antigens and a large
number of clones that recognize antigens with intermediate
abundance in the periphery. The “true” distribution of thymic
output is of course unknown, but it might resemble the one
illustrated in Figure 2B.
The above interpretation for the peripheral T-cell repertoire
of a single individual can be then extended to a whole population
of individuals. In this regard, polymorphisms in genes affecting
physiology of CD4+ T cells (e.g., CTLA-4, CD25, or IL2), might
contribute to individual variation on different model parameters
affecting T-cell immune-physiology (e.g., T-cell proliferation and
death rates). As a consequence, this variation is then translated
into a heterogeneity of the regulation cutoff values present in the
population. In this line of thought, the genetic predisposition of
some individuals to autoimmunity or weak microbial immunity
can be then re-interpreted in terms of variations in the regulation
cutoff. Considering the thymic output shown in Figure 2B as
the reference, individuals with genetic factors implying too-low
regulation cutoffs are expected to be able to maintain too many
Tregs in the peripheral repertoire. The excess of these cells
is likely to suppress beneficial immunity against microbes. On
the other hand, individuals with genetic factors predisposing
to too-high regulation cutoffs are expected to show too many
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unregulated autoreactive clones in the peripheral repertoire. This
situation contributes to the spontaneous onset of an autoimmune
disease. Unfortunately, mathematical modeling cannot per se
resolve the question of what can be considered too low or too
high for the regulation cutoff. On top of that, the regulation
cutoff can only be determined numerically given a set of model
parameters, which brings additional difficulties in studying how
variation in model parameters affects this quantity. However,
for simplicity of the argument, one can easily conceive the
existence of two disease-causing thresholds in a hypothetical
distribution of regulation cutoffs in the population, as illustrated
in Figure 2C. The exact proportion of healthy individuals,
autoimmune patients, and patients with weak antimicrobial
immunity is unknown, but one can speculate that infectious
diseases should, in principle, exert a stronger genetic selection
in the human genome than autoimmune diseases do. If so,
individuals with a high predisposition for an autoimmune disease
are expected to be slightly more frequent in the population than
the ones affected by infections.
Given this basic immunological theory based on the cross-
regulation model, it is reasonable to question where patients
suffering from ME/CFS are placed in the distribution of the
regulation cutoff. On the one hand, patients of this disease
often show clinical symptoms similar to the ones presented by
patients with autoimmune diseases, such as rheumatoid arthritis
and multiple sclerosis (39, 40). On the other hand, patients
suffering fromME/CFS do not develop the disease spontaneously
as expected from a pathology with a strong genetic component.
A classic example of a spontaneous autoimmune disease has
been observed in NODmice whose genetic mutations on CTLA-
4 and CD25 genes elicit type 1 diabetes (41). Instead, patients
suffering fromME/CFS report an infection at their disease onset.
Given this observation, one can hypothesize that these patients
might be healthy individuals who, by chance, were infected with
a microorganism with a strong molecular mimicry to a human
protein. This hypothesis will be discussed below in the context of
the chronic infections by HHV6, HSV1, and EBV.
HYPOTHETICAL IMPACT OF COMMON
HERPESVIRUSES ON CD4+ T-CELL
DYNAMICS AND ITS RELATIONSHIP WITH
ME/CFS
Infections by EBV, HSV1, and HHV6 are highly frequent and
chronic rather than transient in the human populations (24).
Primary infection often occurs during childhood, after which
these viruses enter a chronic phase with some reactivation
over time under stress conditions, as observed in astronauts
(42, 43). However, viruses are often found active in patients
suffering from ME/CFS (4). Consistently with the theory based
on the immunological homunculus (44, 45), these viruses are
able to produce proteins that could mimick dominant self-
antigens (Table 1) (30–32, 34). Antigen mimicry between these
viral antigens and dominant self antigens has then the potential
of initiating and perpetuating an autoimmune disease if the
underlying immune response is not properly regulated. On the
TABLE 1 | Basic information about HHV6, HSV1, and EBV and their putative
impact on the parameters of the cross-regulation model.
Virus HHV6 HSV1 EBV
Age of primary
infection (in years)
0.5–2 (24) Childhood (25) ∼20 (24)
Cell association
during primary
infection
CD4+ T cells (24) Skin epithelial cells
(24)
Oropharyngeal
epithelium, B cells
(24)
Cell association
during latency
Macrophages (24) Neurons (25) B cells (26)
Virus-specific
Tregs
Yes (27) Yes (28) Yes (29)
Possible antigen
mimicry
Myelin basic
protein (30)
Acetylcholine
receptor (31),
α-synuclein (32)
HNRNL (33),
septin-9,
mitochondrial
protein DLST (34)
Possible
mechanism of
immune evasion
Inhibition of
proliferation in
CD4+ T cells
(35, 36)
Inducing of
apoptosis in
activated CD4+ T
cells (37)
Apoptosis/
proliferation of
inhibition of
dendritic and B
cells (26, 38)
Impact on
cross-regulation
model parameters
Decreased
proliferation rate of
Treg/Teff
Increased death
rate of Treg/Teff
Decreased death
rate of cAPC by
T-cell killing
other hand, regulation of the immune response does not promote
clearance of these viruses upon infection. In the context of
the cross-regulation model, the link between viral molecular
mimicry and self-reactivity is understood as function of the total
abundance of the self-antigen and the respective viral antigen
available for T-cell recognition in the body.
Different studies provided evidence for the presence of
Tregs collected from healthy individuals with the capacity of
recognizing and suppressing immune responses against these
common viruses (Table 1) (27–29). To understand the putative
role of Tregs on infection, a steady-state analysis of the extended
cross-regulation model is performed under the assumption that
these viruses are recognized by a single and viral-specific clone
associated with a given cAPC. This assumption is in line with
the notion that these viruses, although becoming chronic, do
not usually lead to severe immunosuppression to the host, as
predicted for viral infections with the capacity of eliminating all
T-cell clones in the peripheral repertoire.
Case I: HHV6
Infections by HHV6 are usually acquired early in life (24). The
virus preferentially infects virus-specific CD4+ T cells inside
which has the capacity of arresting cell cycle (35, 36). Infection
latency is usually associated with macrophages only (24). To
recreate this infection, the proliferation rates of Tregs and
Teffs were reduced as function of the viral dynamics (Table 1).
According to the respective steady-state analysis, four modes of
infections emerge in this scenario.
The first infection mode is related to a high viral carrying
capacity, which strongly reduces the proliferation rates of Tregs
and Teffs of the virus-specific clone. This infection leads to a
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progressive reduction in the density of both Tregs and Teffs,
which culminates with the extinction of the clone (Figure 3A).
On the one hand, clonal extinction of the HHV6-specific clone,
although allowing the virus to become chronic, might promote
a deactivation of the infection due to the exhaustion of the
virus-specific cells sustaining viral replication. If so, this type
of infection might be interpreted as beneficial for the host
and, thus, it could be associated with an individual who has
a dormant or latent virus trapped inside macrophages. On the
other hand, clonal extinction could lead to an uncontrolled
HHV6 infection that, if occurring in the gut, might contribute
to a systemic immune activation due to microbial translocation,
as observed in HIV-infected individuals (46, 47). Such situation
could ultimately promote immune deficiency, a condition not
reported for ME/CFS. Therefore, this mode of infection can be
interpreted as either a healthy or disease state but likely not
related to ME/CFS per se.
The second infection mode is observed when the virus-
specific clone has an intermediate autoimmune potential. In this
case, Tregs of this clone become extinct before infection (owing
to the fact that the respective abundance of cAPC was below
the regulation threshold before infection). In theory, immune
responses elicited by Teffs of this clone toward putative self-
antigens are hypothesized to be under bystander suppression.
The immune response is based on virus-specific Teffs alone
(Figure 3B). On the one hand, these cells provide a cellular source
FIGURE 3 | Four modes of HHV6 infection assuming an infection time at 200. HHV6 is assumed to decrease the T-cell proliferation rate as function of the viral density.
T-cell dynamics in absence of infection were also included for comparison (dashed lines in T-cell plots). (A) Strong infection with a viral carrying capacity of 0.75 and
recognized by a responding clone with a high autoimmune potential (A0 = 4). (B) Moderate infection with a viral carrying capacity of 0.45 and recognized by a
responding clone with an intermediate autoimmune potential (A0 = 1). (C) Mild infection with a viral carrying capacity of 0.2 and recognized by a T-cell clone with a
high autoimmune potential (A0 = 4). (D) Moderate infection with a viral carrying capacity of 0.5 and recognized by a T-cell clone with a high autoimmune potential (A0
= 4). The values for the remaining parameters can be found in Table S1.
Frontiers in Immunology | www.frontiersin.org 6 November 2019 | Volume 10 | Article 2684
Sepúlveda et al. ME/CFS and Immunological Hyper-Regulation by Regulatory T Cells
for viral replication. On the other hand, an immune response
driven by Teffs might generate helper signals that would recruit
other immune cells like natural killer (NK) cells andCD8+T cells
to the infection site. If so, this type of infection can be interpreted
as an immune response that has a lower chance of triggering
either autoimmunity or ME/CFS.
The third infection mode occurs when the virus is recognized
by a responding clone with a high autoimmune potential and
the viral carrying capacity is low. In this case, the proliferation
rates of the Tregs and Teffs from the responding T-cell clone
are slightly affected by the virus. This leads to the maintenance
of both cell types in the responding clone after infection
(Figure 3C). In addition, the resulting steady states of Tregs
and Teffs and their activated counterparts are increased when
compared to a scenario of no infection. As above, the persistence
of virus-specific T cells in an active immune response provides
a continuous cellular source for viral replication. Since activated
Tregs are known to have the capacity of suppressing the cytotoxic
action of NK cells (48), then this mode of infection promotes
a chronically active immune response under control of Tregs.
This contributes to a continuous waste of energy and a persistent
fatigue in the host. In this line of thought, this mode of infection
might be then associated with ME/CFS, as hypothesized in
this article.
The fourth mode of infection also involves the triggering
of a responding clone with a high autoimmune potential,
but alternatively associated with an intermediate viral carrying
capacity (Figure 3D). In this case, the proliferation rates of Tregs
and Teffs of the responding clone are moderately affected but
such alteration is sufficient to induce the extinction of virus-
specific Tregs. Since the responding clone has a high autoimmune
potential, an immune response mounted solely by Teffs is not
regulated and, therefore, it can be interpreted as the hallmark
of an autoimmune disease resulting from an infection. If HHV6
is able to reach the brain and express a protein similar to
the myelin basic protein (Table 1), then this mode of infection
might initiate multiple sclerosis, an autoimmune disease whose
clinical symptoms greatly overlap with the ones reported bymany
patients with ME/CFS (39). In this line of thought, the density
of Tregs is expected to be affected by different viral capacities
of the infecting HHV6, which may contribute to differences in
pathogenesis and subsequent case definitions between multiple
sclerosis and ME/CFS. It is important to note that persistent
fatigue might be present in patients with different pathologies,
including autoimmune diseases, cancer, or even eating disorders.
However, chronic fatigue explained by any known disease,
immune-mediated or not, is an exclusion criterion in current case
definitions for ME/CFS diagnosis and research (1, 2). Therefore,
the interpretations of the above infection modes might be biased
according to these same case definitions.
Case II: Herpes Simplex Virus Type I
In most cases, HSV1 is transmitted orally during childhood
and/or adolescence (24). The main cellular targets of this virus
are the skin epithelium cells and neurons during active and latent
infections, respectively (24, 25). HSV1 is also known to induce
apoptosis in infected monocytes and virus-specific CD4+ T cells
(41). Given this line of evidence, the infection by this virus is
then recreated in the cross-regulation model by an increase in
the T-cell death rates as function of the viral dynamics (Table 1).
Since increasing a death rate has a similar qualitative effect as
decreasing a proliferation rate, the different modes of infections
described for HHV6 can be again recreated for HSV1, but with
some differences in the respective interpretations. The major
difference between these two infections is the timing of the
primary infection. In the case of HSV1, a later primary infection
is more likely to occur when the responding clone might be
already in equilibrium in absence of infection.
Similar to the infection mode shown in Figure 3A, an
infection with a strong impact on the death rate of Tregs and
Teffs implies a decrease in the density of Tregs and Teffs,
which ultimately leads to the extinction of the responding clone
(Figure 4A). However, since the main targets of HSV1 are the
skin epithelium cells and neurons, this clonal extinction might
lead to an uncontrolled infection only sustained by the cytotoxic
action of other effector immune cells that do not require any
helping signals from the CD4+ T cells. In a situation where
these backup cells fail to sustain the infection, this immunological
phenotype might be interpreted as a severe clinical condition,
such as the herpetic stromal keratitis (49).
As illustrated in Figure 3B, the second mode of infection
is associated with an intermediate viral carrying capacity
and recognized by a responding clone with an intermediate
autoimmune potential whose Tregs become extinct before
infection (Figure 4B). Again, it is hypothesized that putative
autoimmune responses induced by this clone before and during
infection are under check by bystander suppression. This
infection implies a moderate increase on death rate of Teffs of
the responding clone and, therefore, these cells can persist during
the immune response and be used as a cellular source for viral
replication. However, activated Teffs are able to send signals and
recruit other immune cells that could limit the pathology of
this infection and promote viral latency. In this line of thought,
this mode of infection has a low probability to degenerate into
ME/CFS or an autoimmune disease.
Again, the remaining two modes of infection are associated
with a responding clone with a high autoimmune potential.
Acetylcholine receptor and α-synuclein are two possible human
proteins with possible molecular mimicry with HSV1 proteins
(31, 32). Similar to the situation recreated in Figure 3C, if the
virus induces a mild increase in the death rates of Teffs and
Tregs, then the respective immune response is characterized
by a cross-regulation between these cell types (Figure 4C). As
interpreted above for the HHV6 case, the persistence of CD4+
T cells in the immune response provides a cellular source for
viral persistence, thus contributing to chronic active infection.
More importantly, the densities of activated Teffs and Tregs
are substantially increased in equilibrium (e.g., chronicity) when
compared to absence of infection. This is consistent with a
chronic inflammation and persistence fatigue. In contrast, if the
infection is associated with an intermediate viral carrying (thus
increasing the T-cell death rate moderately), then the respective
immune response is mounted by Teffs only due to the extinction
of Tregs in the same clone (Figure 4D). This mode of infection
can be then linked to the onset of an autoimmune disease, such
as myasthenia gravis (50).
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FIGURE 4 | Four modes of HSV1 infection assuming an infection time at 1,000. HSV1 is assumed to increase the T-cell death rate as function of the viral density.
T-cell dynamics in absence of infection were also included for comparison (dashed lines in T-cell plots). (A) Strong infection with a viral carrying capacity of 0.75 and
recognized by a T-cell clone with a high autoimmune potential (A0 = 4). (B) Moderate infection with a viral carrying capacity of 0.45 and recognized by a T-cell clone
with an intermediate autoimmune potential (A0 = 1). (C) Mild infection with viral carrying capacity of 0.2 and recognized by a T-cell clone with a high autoimmune
potential (A0 = 4). (D) Moderate infection with a viral carrying capacity of 0.5 and recognized by a T-cell clone with a high autoimmune potential (A0 = 4). The values
for the remaining parameters can be found in Table S1.
Case III: Epstein–Barr Virus
Infections by EBV are ubiquitous worldwide as evidenced by
the high prevalence of antibodies against multiple EBV proteins
in adults and the high frequency of healthy blood donors
with detectable viral DNA (51). Primary infection is often
asymptomatic in infants but frequently results in infectious
mononucleosis in adolescents and adults (24). The preferred
cellular targets are B cells in which the virus has the capacity of
inhibiting proliferation or apoptosis (26). B cells are typically seen
as antibody-producing cells but yet they have also an important
role as antigen-presenting cells to CD4+ T cells due to the
expression of major histocompatibility class II molecules (52).
In this scenario, the effect of EBV infection is described by a
T-cell killing of infected cAPC (Table 1). Again, four modes of
infections emerge from the respective steady-state analysis.
As shown in Figures 3A, 4A for HHV6 and HSV1, the first
mode of infection is associated with a virus with the capacity of
extinguishing the responding T-cell clone (Figure 5A). This only
occurs when the virus has the capacity of killing cAPC directly
in absence of any T-cell response against cAPC themselves.
There is then a quick reduction of cAPCs, which are unable to
maintain the responding clone. Again, clonal extinction might be
interpreted as a situation of uncontrolled infection. However, the
density of cAPCs (e.g., B cells) is very low in equilibrium, which
in principle limits the quantity of viruses that can be reactivated
during latency. In this line of thought, most of available viruses in
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FIGURE 5 | Four modes of EBV infection assuming an infection time at 1,000. EBV is assumed to have a direct impact on the dynamics of cAPC (in this case, B
cells). T-cell dynamics in absence of infection were also included for comparison (dashed lines in T-cell plots). (A) Strong infection with a viral carrying capacity of 0.75,
recognized by a T-cell clone with a high autoimmune potential (A0 = 4) and lack of T-cell capacity in killing infected cAPC. (B) Moderate infection with a viral carrying
capacity of 0.45 and recognized by a T-cell clone with an intermediate autoimmune potential (A0 = 1) (T-cell killing rate of infected cAPC fixed at 0.1). (C) Mild infection
with a viral carrying capacity of 0.2 and recognized by a T-cell clone with a high autoimmune potential (A0 = 4) (T-cell killing rate of infected cAPC fixed at 0.05). (D)
Moderate infection with a viral carrying capacity of 0.5 and recognized by a T-cell clone with a high autoimmune potential (A0 = 4) (T-cell killing rate of infected cAPC
fixed at 0.5). In plot (A), the “growth” of cAPC as a function of the virus was set at −5. A negative growth can be interpreted as the direct killing of cAPC. For plots
(B–D), the growth of the cAPC as a function of the virus was fixed at 4. This means that the virus does not have the ability to kill the cAPC directly, allowing these cells
to grow upon infection.
this type of infection are likely to enter into a latency stage, thus
not causing any persistent pathology.
Similar to Figures 3B, 4B, the second mode of infection
induces an immune response of a clone with an intermediate
autoimmune potential (Figure 5B). Tregs in this clone vanished
before infection but autoimmune responses by the remaining
Teffs might be avoided by bystander suppression. The immune
response against EBV is then mounted by Teffs only. Again,
an immune response based on Teffs only is likely to
recruit other effector immune cells that ultimately would
contribute to a reduction of the infection burden in the
host. If so, this scenario can be then interpreted as an
immune response that has a diminished chance to cause
any pathology.
As illustrated in Figures 3C, 4C, the third mode of infection
is associated with a responding clone with a high autoimmune
potential and a low T-cell killing rate of cAPC (Figure 5C).
This is a situation where the immune response against EBV
is characterized by a cross-regulation between Teffs and
Tregs. More importantly, the densities of Tregs and their
activated counterparts at equilibrium (e.g., chronicity) are
slightly increased when compared to absence of infection. Again,
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increased activation contributes to a chronic inflammation and
persistent fatigue.
The fourth mode of infection is also associated with an
immune response against EBV driven by a responding clone with
a high autoimmune potential (Figure 5D). However, if Teffs are
able to kill the infected APC at a moderate rate, this leads to
a decrease in the density of cAPC. In turn, the decrease in the
cAPC density promotes the extinction of Tregs in the responding
clone. As for HHV6 and HSV1, this mode of infection might be
associated with an autoimmune disorder.
Common Infections Promote a Large
Number of Combinations of Possible
Regulated and Non-regulated Autoimmune
Responses
The above steady-state analyses showed four qualitative modes
of infection for each virus. Since most individuals are known
to be exposed to all these viruses during their lifetime, it is
important to consider all possible combinations of qualitative
immune responses against HHV6, HSV1, and EBV infections
that can occur in the same individual. There is then a total of
64 (=43) possible combinations of modes of infection for these
three viral infections in the same individual. To help interpret
these combinations in terms of health, autoimmune disease, and
ME/CFS, the qualitative interpretation of the immune response
against each viral infection is scored as follows: 0 for a mode of
infection where the responding clone go extinct, 0.5 for a mode
of infection triggering the response of a clone with a moderate
autoimmune potential, and 1 for a mode of infection triggering
the response of a clone with a high autoimmune potential, as
illustrated in Figures 3–5. These scores for individual infections
in the same individual allow the generation of an overall
autoreactivity index for each one of the 64 combinations by
summing the autoreactivity potential of the modes of infection
associated with each virus (Table S2). The possible values for
this autoreactivity index are 0, 0.5, 1, 1.5,. . . , up to 3, where
0 indicates a combination of the three infections in the same
individual where all responding clones would go extinct, and
3 indicates combinations of the three infections in the same
individual, where each virus induced the response of a clone with
a high autoimmune potential (under or not Treg regulation).
Assuming a cumulative effect of these infections on a fatigue
scale or fatigue persistence in a particular individual, an overall
autoreactive index higher than 1.5 indicates a predominance
of infections triggering autoimmunity in the same individual,
therefore being more than associated with ME/CFS and a
putative autoimmune disease. In this line of thought, there are
26 combinations of immune responses in the same individual
without an autoimmune pathology or ME/CFS (Figure 6A). The
remaining 38 combinations can then be associated with either
an autoimmune disease or ME/CFS. For a matter of simplicity,
an autoimmune disease is here defined by all combinations
of infection modes in the same individual where there is a
higher number of immune responses against these viruses,
mounted by autoreactive Teffs under no regulation of Tregs
(n = 19; Figure 6A). In contrast, ME/CFS is defined as a
predominance of immune responses to these viruses exerted
by clones with autoimmune potential but under regulation
of Tregs. There are 10 combinations of immune responses
against the three viruses under this condition (Figure 6A).
Finally, there are nine combinations of immune responses
in the same individual, where there is an even number of
individual autoreactive immune responses regulated and non-
regulated. These combinations, although undefined in terms of
a predominance of cross-regulation or autoimmunity, are likely
associated with chronically active infections. On the one hand,
chronic activation of the immune system is likely to cause fatigue.
On the other hand, persistent active infections are likely to
manifest themselves by a higher frequency of symptoms related
to viral infections often reported by patients with ME/CFS. In
this line of thought, these combinations of immune responses can
be seen as part of the large spectrum of symptoms presented by
patients with ME/CFS.
Quantitative Predictions for the Number of
Tregs in Patients Suffering From ME/CFS
After defining which combinations of infection modes are more
consistent with each clinical condition, the cross-regulation
model can be used to make predictions for the density of Tregs
and Teffs in healthy controls, patients suffering from a putative
autoimmune disease, or patients suffering from ME/CFS. These
predictions are useful for data interpretation given the lack of a
reliable biomarker for ME/CFS.
For illustrative purposes, a simulation of the CD4+ T-cell
repertoire was performed for 500 uninfected healthy controls,
500 infected individuals who do not suffer from an autoimmune
disease or ME/CFS, 500 infected patients suffering from an
autoimmune disease, and 500 infected patients suffering from
ME/CFS. A detailed description of the simulation procedure can
be found in Supplementary File.
According to this simulation, patients suffering fromME/CFS
had, on average, a slightly higher density and percentage of
Tregs than individuals from the remaining groups (Figures 6B,C
and Table S3). Therefore, the definition used for ME/CFS is
consistent with available data from the clinic. On average, there
was a higher density of activated T cells in patients with either
ME/CFS or a putative autoimmune disease when compared
to healthy controls (Figure 6D). However, when the respective
cell densities were converted into percentages, all groups had
a similar average percentage of activated T cells (Figure 6E).
This result suggested that the crude immunological analysis
based on percentage data alone might mask potentially relevant
differences between healthy controls and patients suffering
fromME/CFS.
CONCLUDING REMARKS
This article discussed the overlooked role of Tregs on the
pathology of ME/CFS using the cross-regulation model and
its variant for viral infections. In particular, the discussion
focused on the impact of HHV6, HSV1, and EBV infections,
as these viruses are highly prevalent in human populations,
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FIGURE 6 | Possible definitions of patients with a putative autoimmune disease or with ME/CFS and the corresponding model simulations for densities of Tregs and
activated T cells. (A) Frequency of possible combinations of qualitative immune responses against HHV6, HSV1, and EBV infections in the same individual that
generate each possible value for autoreactivity index. Using this index, individuals who are neither an autoimmune nor a ME/CFS (nAUTO/ME/CFS) patient are defined
by all combinations of infections that have an overall autoimmunity index ≤1.5. Individuals with either ME/CFS or a putative autoimmune disease are in turn associated
with an autoreactivity index >1.5. Individuals with ME/CFS are defined by all combinations of infections where there is an equal or higher number of autoreactive
responses under control of Tregs. Individuals with an autoimmune disease are defined otherwise. (B,C) Boxplots of the density and percentage of Tregs in simulated
data from 500 uninfected healthy individuals, 500 infected nAUTO/ME/CFS individuals, 500 patients suffering from a putative autoimmune disease, and 500 patients
suffering from ME/CFS. (D,E) Boxplots of the density and percentage of activated T cells in the same simulated data shown in (B,C). The boxplots represent the
minimum (lower whisker), the 25% quantile (lower hinge of the box), the median (central horizontal line within the box), the 75% quantile (upper hinge of the box), and
the maximum (upper whisker) of the simulated data.
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thus being major candidates for triggering ME/CFS. Other
viruses such as herpes simplex virus 2 and cytomegalovirus
have also been reported as alternative disease triggers (4).
However, since the prevalence of these lesser common viruses
vary considerably across countries (53–55), they might represent
triggers of ME/CFS in specific populations. This highlights the
difficulty of identifying a master infection other than HHV6,
HSV1, and EBV that could trigger ME/CFS. In this line of
thought, the onset of both ME/CFS and a given autoimmune
disease was hypothesized as the result of a cumulative effect
of autoreactive immune responses to these common viral
infections. In particular, the pathogenesis of ME/CFS was
hypothesized as a predominance of antiviral responses by
autoreactive clones under control of Tregs. This hypothesis is
quantitatively translated into a high density and percentage
of Tregs in patients with ME/CFS when compared to healthy
controls and patients with a putative autoimmune disease,
as illustrated with model simulations and real data from the
clinic (15–17). In addition, an increased regulation by Tregs
might also lead to reduced microbial immunity in patients
with ME/CFS. This expectation is also in agreement with the
frequent viral infections reported by patients suffering from
this disease (3). In the same line of evidence, a recent study
found defective T-cell responses to EBV in patients of this
disease (56).
For discussing the role of Tregs on ME/CFS, simplifying
assumptions were made for the construction of the cross-
regulation model. The most important one was to not distinguish
the dynamics of natural and inducible Tregs. Therefore, the
discussion could only be done for Tregs as a whole. In theory,
modeling the dynamics of natural and induced Tregs is expected
to improve the insights into ME/CFS. It is known that these
two cell types have distinct biology and molecular requirements
for their function and cell survival (57). Natural Tregs require
co-stimulation with CTLA-4 and are typically associated with
IL-2 expression, whereas inducible Tregs typically exert their
regulatory function in immunological niches enriched with
TGFβ. Given these observations, a more detailed extension of
the cross-regulation model could be used not only to investigate
the dynamics of natural and induced Tregs during a viral
infection but also to determine the expected relationship with
the resulting cytokine expression profiles. This could help to
identify specific cytokine signatures associated with ME/CFS.
Until now, the most reported cytokine in ME/CFS literature
is TGFβ, whose expression tends to be increased in patients
suffering from this disease (18, 19). A systematic review also
provided some evidence for an increased IL-2 expression in
patients with ME/CFS, but most of these studies were statistically
inconclusive (18). In face of these different studies, ME/CFS
could result from an increased regulation of induced Tregs
supported by active HHV6, HSV1, and EBV infections. A way
to test this hypothesis is to investigate a possible molecular
mimicry between viral and human proteins given that Tregs
are thought to target tissue antigens. Then, the existence of
specific Tregs recognizing such target proteins should be assessed
in patients suffering from ME/CFS and compared with healthy
controls. If so, healthy controls are expected to have a lower
fraction of these specific cells within the Treg pool than patients
suffering from ME/CFS. This type of investigation has already
been attempted for type I narcolepsy, an autoimmune disease
that can be triggered by a molecular mimicry between the
human hypocretin protein and proteins from H1N1 influenza
A virus (58). In agreement with the proposed hypothesis,
patients suffering from this autoimmune disease tend to have,
on average, an increased number of Tregs than healthy controls
(59). With respect to ME/CFS, a putative molecular mimicry was
recently suggested between an EBV-derived peptide (EBNA6),
human thyroid peroxidase, and other human proteins (60).
However, it is still unclear whether other viruses associated
with ME/CFS (4) would induce similar molecular mimicry with
tissue antigens.
In this discussion, the CD4+ T-cell repertoire was assumed
to be composed of independent clones, each one of them with
a specific dynamic determined by a specific cAPC available
at a given abundance in the periphery (20). In theory, these
independent clones are required to recognize non-overlapping
sets of antigens through their T-cell receptors or to interact
with mutually exclusive sets of cAPCs. This assumption is
unrealistic for non-specific antigen presentation provided by
macrophages and dendritic cells. However, specific antigen
presentation is less likely to occur in viral infections where a
more specialized immune response might be required. In the
context of infections, B cells are known not only to produce
antibodies involved in pathogen clearance, but also to enhance
ongoing immune response by performing highly specialized
antigen presentation to CD4+ T cells (52). In this scenario, the
assumption of independent T-cell clones with distinct sets of
cAPCs can be re-interpreted as a possible interaction between
two highly specific cellular repertoires, one related to CD4+
T-cells and another related to B cells serving as their cAPCs.
If so, the theory based on cross-regulation model can help
interpret the potential effects of current therapies based on B-
cell depletion on patients with ME/CFS or with multiple sclerosis
(60–63). The basic idea of these therapies is to eliminate B
cells in order to have a re-population of the periphery with
a new B-cell repertoire generated from the bone marrow.
These therapies then induce a reduction of specific antigen
presentation to CD4+ T cells carried out by B cells. If this
reduction affects all B-cell clones irrespective of their antigen
specificity, then the distribution of cAPC density associated
with a given individual (Figure 2B) is expected to shrink
upon treatment. According to the cross-regulation model, such
therapeutic reduction in cAPC density would promote a slow
depletion of Tregs together with a reduction in the number
of Teffs belonging to the same highly autoreactive clones. If
ME/CFS is indeed related to a hyperregulation of CD4+ T-
cell responses toward common viruses, then this depletion is
expected to bring some benefits to the respective patients. On
the other hand, a reduction in antigen presentation by B cells
might also lead to a depletion of many T-cell clones with
an intermediate autoimmune potential in which the resulting
density of their cAPC would go below the survival threshold
during treatment. If these clones are indeed the main source of
most immune responses, as hypothesized elsewhere (20), their
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depletion might pose a threat to patients if they experience
any infection during treatment. In addition to these effects, the
success rate of treatments based on B-cell depletionmight require
understanding the interplay between the rate by which new B
cells can repopulate the periphery, the frequency by which a
drug is administrated and the rate by which individuals are
normally infected. This interplay should be investigated in future
clinical trials.
Another simplifying assumption in this discussion was to
neglect the impact of a continuous thymic export to the
periphery. In theory, thymic export influences the T-cell
repertoire by introducing new clones into periphery. Given
the high combinatorial nature of the genetic rearrangement
mechanism encoding the T-cell receptor, these new clones should
exhibit different antigen specificities from the ones already
existing in the periphery. Interestingly, early work using a
more complex cross-regulation model demonstrated that most
of the clonal selection shaping the T-cell repertoire occurs
early in life (21). After this time period, the resulting T-cell
repertoire is enriched with resident clones at sufficiently high
density. These resident clones tend to be highly autoreactive
and are able to outcompete newly generated clones typically at
lower densities. In this scenario, the role of thymic export is
only relevant to understand the impact of infections targeting
clones with an intermediate autoimmune potential. Since an
autoimmune disease and ME/CFS were here associated with
clones with a high autoimmune potential, the above results
should not be affected by the inclusion of a thymic output in
the cross-regulation model. A possible limitation of excluding
a thymic export from the model is related to a putative re-
activation of dormant HHV6, HSV1, and EBV infections that
could trigger ME/CFS. Viral dormancy was here interpreted
as resulting from infections with the potential of extinguishing
the responding clone. This interpretation seems particularly
reasonable for HHV6 and HSV1, two viruses associated with
CD4+ T-cell tropism. In these cases, if the thymus generates
a new clone with similar HHV6 and HSV1 antigen specificity,
then this clone might serve as a renewed cellular source
for viral replication. This event might then promote the re-
activation of the existing dormant infections. Again, the high
combinatorial nature of the T-cell receptor rearrangement
mechanism suggests that the re-activation of dormant infection
via the generation of new clone with similar antigen specificity
should be a very unlikely event in individuals without any
genetic abnormality underlying the generation of the T-cell
repertoire. Interestingly, genetic polymorphisms on the locus
encoding the alpha chain of the T-cell receptor were found to
be associated with ME/CFS (64). However, the study of the T-
cell receptor repertoires in patients with ME/CFS remains to
be performed and, therefore, it is still unclear whether these
genetic polymorphisms are indeed in the true causal pathway of
the disease.
A final simplification of this discussion was to assume a single
responding clone against each virus. This simplification is in line
with the concept of immunodominance where only a fraction
of possible epitopes is able to stimulate a T-cell response (65).
Immunodominance can also be defined as the frequency of T
cells targeting individual antigens (66). This is a very useful
concept, because it restricts the analysis to a small number of
viral antigens and clones. For example, lytic cycle antigens are
possible immunodominant targets of CD4+ T cells against EBV
infections (67). In reality, a given infection is likely to trigger a
polyclonal immune response targeting different viral proteins.
This was suggested by a recent study in which the antibody
levels against different EBV-derived peptides were quantified in
patients with ME/CFS (68). In theory, these polyclonal immune
responses can be simulated using the cross-regulation model
under the assumption of independent clones, where each clone
recognizes a given viral protein. However, the simulation of such
a polyclonal immune response, although interestingly, seemed
more appropriate for a study with the specific aim of generating
predictions for the shape of the CD4+ T-cell repertoire in
ME/CFS patients, which was out of the scope of this work.
It is worth noting that the cross-regulation model was the
first one to be developed to understand the immune-physiology
of Tregs specifically (23). Since its first formulation, this model
has been used to explain the hygiene hypothesis for autoimmune
diseases and to tackle tumor immunobiology (69, 70). Other
mathematical models for the dynamics of Tregs also emerged
in the literature, as reviewed in detail elsewhere (71). They
were formulated under different mechanisms, such as APC
maturation and direct suppression of Teffs by Tregs. They offer
then alternative avenues of research to unravel the impact of
Tregs on the pathology of ME/CFS. In the context of a specific
disease, a mathematical model of Tregs dynamics was proposed
for studying multiple sclerosis in humans and experimental
autoimmune encephalomyelitis in lab mice (72, 73). In contrast
with the cross-regulation model, this model described tissue
damage explicitly as well as its relationship with the quantity of
antigen presentation to CD4+ T cells. This feature of the model
led to a stable oscillatory behavior for the respective dynamics,
thus providing a mechanistic explanation for symptoms relapses
typically observed in patients with multiple sclerosis. Similar
relapsing–remitting symptoms are typically observed in patients
with ME/CFS (74) and, therefore, this alternative model might be
redeployed to investigate this disease and its putative differences
with multiple sclerosis.
In conclusion, this discussion is a first attempt to tackle
the pathology of ME/CFS from a mathematical modeling point
of view. It hopes to foster research of this disease beyond
a collection of disparate evidence where disease causality is
difficulty to be ascertained due to possible selection bias and
disease misclassification (75). In this regard, mathematical
modeling under realistic assumptions provides invaluable theory
upon which different hypotheses can be tested. In this article,
the focus of discussion was the specific impact of Tregs
in ME/CFS using a well-established mathematical model.
Alternative hypotheses concerning the role of other immune-
cell populations in ME/CFS are welcome but, bearing in mind,
they can be rigorously assessed by developing an appropriate
mathematical model. In this regard, mathematical modeling
of the immune system has a sufficiently long history to
provide ME/CFS researchers an already-built mathematical
model tailored to their needs (76). As such, mathematical
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modeling shows promise to accelerate the research and treatment
of this complex disease.
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